Brian J King1, Scott C Lester2, Stanislav N Tolkachjov3, Mark D P Davis4, Lawrence E Gibson4, James A Martenson2. 1. Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Surgical Dermatology Group, Birmingham, Alabama. Electronic address: bking@surgicaldermatology.com. 2. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. 3. Surgical Dermatology Group, Birmingham, Alabama. 4. Department of Dermatology, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: Focal or total skin radiation therapy can be used to treat mild to refractory cutaneous T-cell lymphoma. OBJECTIVE: To report the broad therapeutic benefit of radiation therapy for cutaneous T-cell lymphoma. METHODS: Retrospective, single-institution review of outcomes for skin-directed radiation therapy. RESULTS: Skin-directed radiation therapy showed a 99% response rate and 80% complete response rate after treatment regardless of involvement, severity, histopathologic subtype, dose, or fractionation. The overall in-field recurrence rate was 15%, and median time to recurrence was 296 days (range, 1-1884 days). Focal and hypofractionated regimens were similarly associated with disease response and rare toxicity. Short-term rates of secondary skin cancer after treatment were comparable to expected incidence in a patient population without radiation. LIMITATIONS: Large total number of treatments courses compared with overall number of patients. Heterogenous mix of treatment regimens (no standardization of dose or fraction number). CONCLUSIONS: Radiation therapy is a well-tolerated treatment option for properly selected patients with cutaneous T-cell lymphoma.
BACKGROUND: Focal or total skin radiation therapy can be used to treat mild to refractory cutaneous T-cell lymphoma. OBJECTIVE: To report the broad therapeutic benefit of radiation therapy for cutaneous T-cell lymphoma. METHODS: Retrospective, single-institution review of outcomes for skin-directed radiation therapy. RESULTS: Skin-directed radiation therapy showed a 99% response rate and 80% complete response rate after treatment regardless of involvement, severity, histopathologic subtype, dose, or fractionation. The overall in-field recurrence rate was 15%, and median time to recurrence was 296 days (range, 1-1884 days). Focal and hypofractionated regimens were similarly associated with disease response and rare toxicity. Short-term rates of secondary skin cancer after treatment were comparable to expected incidence in a patient population without radiation. LIMITATIONS: Large total number of treatments courses compared with overall number of patients. Heterogenous mix of treatment regimens (no standardization of dose or fraction number). CONCLUSIONS: Radiation therapy is a well-tolerated treatment option for properly selected patients with cutaneous T-cell lymphoma.
Authors: Caitlin M Brumfiel; Meera H Patel; Pranav Puri; Jake Besch-Stokes; Scott Lester; William G Rule; Nandita Khera; Jason C Sluzevich; David J DiCaudo; Nneka Comfere; N Nora Bennani; Allison C Rosenthal; Mark R Pittelkow; Aaron R Mangold Journal: Curr Treat Options Oncol Date: 2021-09-27
Authors: Elizabeth B Jeans; Yue-Houng Hu; Bradley J Stish; Brian King; Mark Davis; William S Harmsen; Kristin M Fruth; Sarah E Locher; Christopher L Deufel; Jaden D Evans; James A Martenson; Scott C Lester Journal: Pract Radiat Oncol Date: 2020-08-08